One BioMed is a technology company.
One BioMed has raised $5.0M across 1 funding round.
One BioMed has raised $5.0M in total across 1 funding round.
One BioMed is a Singapore-headquartered molecular life science startup developing automated platforms for nucleic acid extraction and purification to accelerate biomedical research and clinical testing.[1][2] Its flagship Xceler8™ Solution, including the X8™ HMW DNA Cartridge Kits powered by the OneTouch Instrument, provides a fully automated, walk-away system for extracting high molecular weight DNA from diverse samples like bacteria, plants, tissues, and blood cells, supporting applications such as long-read sequencing.[1][4] The company serves biomedical researchers and clinicians by simplifying workflows, reducing costs, and enabling point-of-care diagnostics for infectious diseases, with early products targeting low-throughput labs and future expansions into multiplexed panels for pediatric respiratory infections, tuberculosis, and mosquito-borne illnesses.[1][5][6]
Founded as a spin-off from A*STAR's Institute of Microelectronics, One BioMed demonstrates rapid growth through patented technologies in chemistry-based extraction and silicon photonics sensing, positioning it as a leader in accessible, high-performance molecular tools.[2][5]
One BioMed emerged as a spin-off from Singapore's A*STAR Institute of Microelectronics (IME), leveraging lab-on-a-chip technology to integrate semiconductor silicon photonics, chemistry, and biology into compact diagnostic systems.[5][6] Dr. Mi Kyoung Park, the Founder & CEO (also noted as Chief Technology Officer in early collaborations), leads the company with expertise in molecular diagnostics, driving its focus on rapid, cost-effective nucleic acid extraction and sensing.[4][5] The idea stemmed from addressing limitations in traditional molecular testing—slow speed, high costs, and central lab dependency—aiming for point-of-care solutions that deliver results in 20 minutes for up to 20 infectious diseases at prices comparable to single central lab tests.[6]
A pivotal moment came in establishing a joint laboratory with A*STAR's Genome Institute of Singapore (GIS) around 2017, funded at S$9 million, to develop multiplexed assays for Asia-prevalent diseases like pediatric respiratory infections, drug-resistant tuberculosis, and dengue.[5][6][7] This partnership provided early traction, combining GIS's genomic expertise with One BioMed's platforms. By May 2023, the company launched its X8™ HMW DNA Cartridge Kits, marking the world's first fully integrated, out-of-the-box automated HMW DNA extraction system.[2][4]
One BioMed rides the wave of decentralized molecular diagnostics and precision medicine, fueled by post-pandemic demand for rapid, point-of-care testing amid rising infectious diseases in Asia, such as tuberculosis and dengue.[5][6] Its timing aligns with advances in long-read sequencing and genome assembly, where high-quality HMW DNA extraction is critical but labor-intensive, enabling broader access to these tools beyond specialized labs.[4] Market forces like Asia's healthcare infrastructure gaps, regulatory pushes for affordable diagnostics, and A*STAR's innovation ecosystem favor its growth, as central labs struggle with speed and cost for real-time data.[6]
The company influences the ecosystem by spinning out IME tech into commercial platforms, partnering with GIS for assay development, and lowering barriers for researchers—potentially accelerating drug discovery, outbreak response, and personalized treatments.[5][7]
One BioMed's trajectory points to expanded clinical adoption, with its PoC infectious disease panels following research-focused products like X8 kits, targeting high-burden Asian markets.[6] Trends in AI-driven genomics, portable biotech hardware, and multiplexed testing will amplify its momentum, potentially through more A*STAR collaborations or global scaling. Its influence may evolve from niche innovator to ecosystem enabler, powering decentralized health transformations that started with a Singapore spin-off committed to accessible biomedical acceleration.[1][4]
One BioMed has raised $5.0M in total across 1 funding round.
One BioMed's investors include ARCH Venture Partners, Waverley Capital.
One BioMed has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series A in July 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2019 | $5.0M Series A | ARCH Venture Partners, Waverley Capital |